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Oncoprotein stability after tumour resection
G. Ong, W. Gullick & K. Sikora
ICRF Oncology Group, Hammersmith Hospital, Du Cane Road, London W12 OHS, UK.
Summary The means by which oncogenes and their products activate malignant tranformation are currently
under intense investigation. However, published papers on experiments using human tumour material do not
always report in detail their methods of collection or storage of the specimens. In order to assess the stability
of oncogene encoded proteins following collection or storage of human tumour biopsies, we have examined
the rate of decay of the c-myc, neu and EGF-receptor proteins. Solid tumours, containing amplified copies of
each oncogene, were established in nude mice and the stability of the oncogene protein in portions of each
tumour, left in phosphate buffered saline at room temperature for varying time intervals, was examined by
immunoblotting. Intact EGF-recptor and neu oncoproteins were present even after 24 h under these conditions
while the c-myc protein was apparently rapidly degraded after 20 min. These data demonstrate that oncogene
products decay at different rates after tumour resection and that collection of human biopsies should take this
into account in order to provide the basis for consistent measurements of protein expression.
There is accumulating evidence that oncogenes, some of
which encode proteins thought to be involved in normal
cellular growth functions, play a role in malignant transfor-
mation. Alterations in sequence or expression of genes such
as c-myc (Slamon et al., 1984), ras (Lemoine, 1990) and
c-erbB-2 (Gullick & Venter, 1989) are associated with several
common solid human tumours. Abnormal expression of the
EGF receptor has also been reported in squamous cell car-
cinomas of cervix, vulva, head and neck, oesophagus, glial
cells, lung and breast.
Since neoplasia may result from the accumlation of multi-
ple oncogenic events (Kahn & Graf, 1988) it is important to
study the pattern of expression of oncogenes in human
tumours. Such studies may identify consistent changes to
particular oncogenes which may be useful in understanding
the mechanisms of carcinogenesis, provide helpful prognostic
information and indicate targets for new forms of therapy.
To date, the extent of expression and localisation of
oncogene products have been routinely analysed in archival
material of patients by semi-quantitative immunohistological
staining. Various methods of fixation have been employed,
and the lapse of time between collection and fixation has not
generally been reported. Since immunohistochemical staining
does not indicate the integrity of the oncoproteins, pro-
teolysis which may have occurred during tumour processing
may lead to diminished staining intensity and an under-
estimate of the degree of oncoprotein expression.
A more quantitative asasy for detecting the presence of a
particular oncogene product which also determines its
molecular weight, and therefore its integrity, is immunoblot-
ting of tumour extracts. In this technique, fresh or frozen
resected tumour tissue is required. We have examined the
decay of some commonly measured oncogene products to
establish their stability in human tumour biopsies stored
under various conditions and for different time periods. The
information obtained will ensure that future studies of
oncoprotein estimation by immunostaining are unlikely to be
invalidated by variable extents of oncoprotein loss.
Materials and methods
Cell lines
The cell lines A431, from a human vulval carcinoma (Stos-
check & Carpenter, 1983), B104 1.1, NIH 3T3 cells trans-
formed with the mutant neu oncogene (Schechter et al., 1984)
and Colo 320 HSR, a human colonic apudoma derived cell
line (Alitalo et al., 1983) express high levels of EGF-receptor,
neu and c-myc proteins, respectively. A431 cells were
obtained from Dr M. Waterfield and B104 1.1 from Profes-
sor R.A. Weinberg. Colo 320 were from the PHLS European
collection of Animal Cell Cultures, Porton Down and EJ6, a
ras transformed NIH 3T3 cell line overexpressing the H-ras
protein, was a kind gift from Dr Nick Lemoine.
Antibodies
BG16, a polyclonal antibody directed at the synthetic peptide
2E, residues 985-996 (Kris et al., 1985), was employed to
identifiy the EGF receptor. Antibody 21N (Gullick et al.,
1987), a polyclonal antibody directed against a synthetic
peptide 21N, residues 1243-1255, was used to detect the neu
protein. The monoclonal antibody 9E10 (Evans et al., 1985)
directed against a synthetic peptide G, residues 408-439, was
employed to identify the c-myc product. 9E10 was obtained
from Cambridge Research Biochemicals, UK. The H-ras
gene product was detected using the Y13-259 monoclonal
antibody (Furth et al., 1987) obtained from Oncogene
Science Inc., New York, USA.
Tumour production andprocessingfor Western blots
Nude mice were injected subcutaneously with tumour cells
(5 x 107) from cell lines A431, B104 1.1, Colo 320 HSR or
EJ6. Tumours were removed after the mouse was killed and
cut into four to eight portions.
Tumour segments were left to stand in phosphate buffered
saline (PBS) at time intervals from 0 to 24 h at room
temperature. Segments from another tumour were snap
frozen in liquid nitrogen, transported in dry ice for 2-3 h,
then stored in liquid nitrogen. These were then allowed to
thaw and were left for time intervals between 0 and 24 h at
room temperature before analysis.
Control segments from another tumour, used immediately
after removal, were analysed to determine whether the
oncoprotein expression was uniform throughout the tumour.
Sections were homogenised in lysis buffer (containing
50 mM Tris/HCI buffer, pH 7.4, 1% Triton X-100, 0.5 mM
EGTA, 150 mM NaC 1, 25 mM benzamidine and 3 mM
PMSF) and the protein concentration was determined by the
Bradford dye binding assay (Bradford, 1976). Western blot-
ting was performed essentially according to Towbin et al.
(1979).
A total of 50 yg of protein from each tumour segment was
electrophoresed on 5% SDS polyacrylamide gels for A431
and B1041.1 tumours and 10% gels for Colo 320 tumours.
Gels were then equilibrated for 30 min in Electroblot buffer
(25 mM Trizma base, 192 mM glycine, 0.01% SDS and 20%
methanol). Size fractionated proteins were electroblotted
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onto nitrocellulose for 3 h at 180 V, 0.06A. Blots were
blocked in TBST (10 mM Tris/HC1 buffer, pH 8.2, 150 mM
NaCl, 0.05% Tween 20) containing 2% non-fat dried milk
(Marvel, Cadbury, UK) for 1 h and then incubated for 16 h
at 4°C with shaking with primary antibody diluted in TBST.
Antibody BG16 was used at a dilution of 1:200 of whole
serum, 21N at a concentration of 6 ,tgml ' and 9E10 at a
dilution of 1:100. Blots were then washed in TBST three
times, each for 10 min, and then incubated with second
antibody. The second antibody conjugated with alkaline
phosphatase was obtained from Promega Biotech USA
(agents P and S Biochemicals Ltd, Liverpool, UK). Incuba-
tion with second antibody and colour development was per-
formed according to their instructions which accompanied
the kit.
In the case of the c-myc product, tumour segments were
crushed to a powder while frozen and then scooped into a
different lysis buffer containing 25 mM Tris/HCl, pH 8.0,
150 mM NaC1, 1% aprotinin (Sigma), 0.5% soya bean tryp-
sin inhibitor (Sigma), 3 mM PMSF and 1% SDS. The
suspension was thoroughly homogenised by forcing it
through a syringe and needle several times. Protease
inhibitors were essential to prevent breakdown of the myc
protein during homogenisation. The addition of 1% SDS was
necessary to release all the c-myc proteins from the nucleus.
Densitometer scans on immunoblots made transparent
with three-in-one lubricating oil (Maciewicz & Knight, 1988)
were carried out to quantitate the extent of protein expres-









Using immunohistological staining, it has sometimes been
observed that regional variations in oncoprotein expression
occur in human and animal tumours. Since we wished to use
segments of individual tumours to analyse oncoprotein
breakdown we first determined whether expression varied
between tumour slices. Consequently, Western blots were
performed using cell extracts obtained from all the segments
of one tumour homogenised immediately after resection.
While there is slight variation in the intensity of the bands,
there is, overall, equal regional distribution of each of the
oncogene products in all the randomly cut sections of the
tumour (Figures la, 2a and 3a). We therefore went on to
examine the stability of the oncogene products at various
time intervals after resection.
The stability of each oncogene protein was determined by
preparing extracts of similar sized tumour segments left for
various times in PBS at room temperature. Figure lb and c
show that the EGF receptor protein was still present afer
24h incubation, whether the time intervals were initiated
directly after tumour removal or when the tumour was
thawed out at room temperature after storage in liquid nitro-
gen. Densitometer scans, obtained from the blots of the EGF
receptor protein (Figure ld), showed some variation in the
amounts present at each time point but that there was no
progressive disappearance of the EGF receptor protein with
time since the signal levels were within the limits of variation
obtained with the control blot (Figure la). Two EGF-
receptor protein bands were observed in extracts of solid
tumours of A431 cells (Figure la, lanes 1-8; Figure lc, lanes
1-7). It has been reported that the protease calpain is pre-
sent in the cytoplasm of many mammalian cells and that in
the presence of calcium, this will cleave detergent solubilised
EGF receptors to a species which runs at 150,000 mol.wt
(Cohen et al., 1982). Despite including the calcium chelator
EGTA in the tumour homogenisation buffer to inhibit this
enzyme, two bands were generally obtained but with
noticeably different intensities in extracts of different tumours
and the lower band was sometimes absent. This doublet has
also been observed in tumour extracts of a squamous cell
carcinoma of the cervix (Gullick et al., 1986).
The stability of the neu protein is shown in Figure 2b and
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Figure 1 Stability of the epidermal growth factor receptor
studied by Western blotting. a, Eight tumour segments (lanes
1-8) prepared from a single tumour zenograft of A431 cells used
immediately after removal from the mouse. Lane 9, lysate
prepared from cultured A431 cells. Lane 10, molecular weight
markers: a, myosin 200,000 mol. wt; b, phosphorylase b 92,500;
c, bovine serum albumin 68,000; d, ovalbumin 43,000. Arrow
shows the position of the EGF recepetor. b, Seven tumour
segments (lanes 1-7) from an A431 cell zenograft left for the
indicated time periods prior to homogenisation and analysis.
Lane 8, A431 cell lysate. Lane 9, myosin 200,00 mol. wt. c, Seven
tumour segments (lanes 1-7) from an A431 cell zenograft stored
in liquid nitrogen, thawed then left for the indicated time periods.
Lanes 8 and 9 as in b, d, Densitometer scans of the Western blots
shown in a-c as indicated. The area under the peak is plotted in
arbitrary units. 0 blot a; * blot b; * blot c.
the oncoprotein had not diminished detectably. Again the
densitometer scans (Figure 2d) support these findings since
the levels of expression and their variation are similar to
those shown in the control blot (Figure 2a).
In intitial experiments using time periods up to 24 h, the
c-myc protein was found to be relatively unstable since the
signal obtained was drastically reduced in intensity after
storage of the tumour segments for 2 h at room temperature.
We therefore examined shorter time periods at more frequent
intervals (Figure 3b and c). It would appear from the den-
sitometer scans (Figure 3d) that the c-myc product is sub-
stantially degraded between 20 and 60 min after removal of
the tumour. This pattern of decay was repeatedly obtained
with tumours from different mice. As shown in Figure 3b
0 I I I-l l |540 G. ONG et al.
a
1 2 3 4 5 6 7 8 9
1 2 3. 4 5 6 7 8
b
1 2 3 4 5 b 7 a 9
&% 0 4 8 12 16 20 24
0 20 60 120
1 2 3 4 5 7
























Figure 2 Stability of the neu protein studied by Western blot-
ting. a, Lanes 1-6, tumour segments prepared from a zenograft
of B104 1.1 cells used immediately after removal. Lane 7, lysate
prepared from cultured B104 1.1 cells. Lane 8, molecular weight
markers: a, myosin 200,000 mol wt; b, phosphorylase b 92,500; c,
bovine serum albumin 68,000; d, ovalbumin 43,000. Lane 9,
lysate prepared from the cultured human breast cancer cell line
SKBR-3, a cell line expressing high levels of c-erbB-2 protein,
190,000 mol. wt. The arrow indicates the position of the neu
protein. b, Lanes 1-7, B104 1.1 tumour segments left for the
indicated time periods. Lane 8, lysate from cultured B104 1.1
cells. Lane 9, myosin 200,000 mol. wt. c, Lanes I -7, B104 1.1
tumour segments stored frozen in liquid nitrogen, thawed and left
for the indicated time periods. Lane 8, lysate from cultured
B104 1.1 cells. Lane 9, Lysate from cultured SKBR-3 cells. Lane
10, myosin 200,000 mol. wt. d, Densitometer scans of the Western
blots shown in a-c as indicated. The area under the peak is
plotted in arbitrary units. 0, blot a; *, blot b; * blot c.
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Figure 3 Stability of the c-myc protein studied by Western blot-
ting. a, Lanes 1-6, tumour segments prepared from a zenograft
of Colo 320 cells used immediately after removal. Lane 7,
molecular weight markers: a, myosin 200,000 mol. wt; b, phos-
phorylase b 92,500; c, bovine serum albumin 68,000; d, oval-
bumin 43,000; e, carbonic anhydrase 30,000; f, trypsin inhibitor
21,500. Lane 8, lysate from cultured Colo 320 cells. Arrow shows
position of the c-myc protein. b, Lanes 1-4, Colo 320 tumour
segments left for the indicated time periods before homogenisa-
tion and analysis. c, Lanes 1-4, Colo 320 tumour segments
stored frozen in liquid nitrogen, thawed and left for the indicated
time periods before homogenisation and analysis. d, Densitometer
scans of the Western blots shown in a-c. The area under the
peak is plotted in arbitrary units. 0, blot a; *, blot b; *, blot
c.
and c, there was no difference in this pattern whether the
tumours were used directly after dissection or thawed out
from storage in liquid nitrogen. The control blot (Figure 3a)
shows equal distribution of c-myc protein throughout the
tumour so the pattern of disappearance of the protein cannot
be attributed to non-homogeneous expression of the
oncogene product. There are other less intense bands recog-
nised by the antibody apart from the p62000 band (Figure
3a). These could be non-specific binding of the antibody to
proteins peculiar to growth of the tumour in nude mice since
they have been observed to vary in quantity from mouse to
mouse and are absent in some tumours and in the Colo 320
cell line extract (Figure 3a, lane 8).
A different tumour was used for each of the gels in Figures
la-c, 2a-c and 3a-c. Reproducibility of results was
obtained in at least three tumours from three different
animals for each of the gels in Figures lb, c, 2b, c, 3a, b and
c. For each of the control blots (Figures a and 2a), the
experiment was performed on two tumours from two
different animals with similar results.
While the H-ras protein was detectable as a weak band in
immunoblots prepared from cultured EJ6 cells, the amount
of ras protein detected in the tumour tissue was lower,
producing extremely faint bands in the immunoblots (data
not shown). We could not, therefore, accurately determine
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signal obtained, several experiments suggested that the H-ras
protein was still present after 24 h. However, additional
experiments are needed using cells expressing higher levels of
the H-ras protein to confirm this.
Discussion
Amplification or abnormal expression of oncogenes are com-
monly found in human tumours. By evaluating the functions
of oncogenes in normal cells and the temporal sequence of
the interrelated events by which each oncogene contributes to
transformation we may begin to understand the phenomenon
of carcinogenesis. Much of the clinical research on human
cancer involves the analysis of oncoprotein levels found in
resected tumour material. Such studies do not often record
how quickly tumours were collected and frozen after resec-
tion. There is, therefore, a need to determine whether varia-
tions in collection and storage of clinical material affects
oncoprotein degradation. Future studies may therefore em-
ploy appropriate conditions which do not cause unnecessary
and unknown alterations in the measured levels of onco-
protein expression.
We have modelled the problem by employing, where possi-
ble, human tumour cell lines expressing particular oncogene
products. For ease of detection we have chosen lines that
contain elevated levels of oncoprotein. It has been assumed
that the rate of degradation of a particular protein is not
affected radically by its level of expression. In these
experiments the solid tumours were cut into fragments and
stored for varying periods in PBS at room temperature.
Although these conditions closely mimic those commonly
employed in operating theatres they do not address some
other potentially important factors. Variations in autolysis
rates inevitably occur between different tissues, for example
high rates of degradation are found in pancreatic tissue due
to release of digestive enzymes such as trypsin. Secondly, we
have deliberately looked at time periods up to 24 h to model
postmortem tissue degradation since it may be desirable to
examine oncoprotein levels in tissues containing distant
metastatic tumour deposits not normally biopsied. The con-
ditions we have employed do not account for rates of oxygen
consumption or tissue cooling which will be different in
tissues in situ.
The stability of a particular oncoprotein in live cells does
not necessarily predict its rate of degradation in dying tissue.
The balance between protein synthesis and the natural rate of
degradation will be altered in anoxic, moribund cells leading
to a progressive reduction in intact protein levels at an
unpredictable rate. Despite this we have found that the decay
of oncogene products in resected tissue is not far different
from their natural half-life. The EGF-receptor protein has a
half life of 10 h (Stoscheck & Carpenter, 1984) and our
studies show that the protein is still stable after 24 h. The neu
protein, which has a half-life of about 7 h (Hudziak et al.,
1989), is also stable up to 24 h from our experiments.
The c-myc protein has a natural half-life of about 30 min
(Ramsay et al., 1984). In our experiments c-myc starts to
decay between 20 min and 1 h, at which time it is no longer
detectable on immunoblots. Although we cannot draw
definite conclusions about the stability of the ras gene pro-
duct, it would appear that it is still present after 24 h.
We have found that frozen tumour fragments left to thaw
for 24 h in PBS displayed autolysis, although no autolysis
was evident after 20 min. c-erbB-2 expression can still be
detected by immunostaining in human fetuses 24 h post-
mortem despite obvious autolysis (P. Quirke, personal com-
munication). Our Western blot results suggest that degrada-
tion of the c-myc protein begins after 20 min and by 1 h the
c-myc product has been substantially degraded. Therefore,
one could not confidently assay for c-myc expression after
20 min when resected tumour tissue still appears intact,
whereas for c-erbB-2 and EGF-receptor, one could still detect
the proteins even when resected tissue has undergone
autolysis. In the light of these experiments, it would be
worthwhile for future studies on oncogene expression in
human tumours to follow standard procedures for tumour
collection if useful interpretation is to be made of the data.
In addition, these results suggest that studies on the pat-
tern ofexpression of the c-erbB-2 and EGF-receptor could be
examined in metastatic disease. The mechanisms involved in
metastasis are not known and may be similar to or different
from those initiating transformation.
In the clinical situation where patients relapse some
months or years after removal and treatment of the primary
tumour, distant metastasis can occur at mulitple secondary
sites throughout the body. In such instances, death usually
results from failure to respond to drug therapy. Thus there is
an urgent need to develop new forms of treatment for this
group of patients. To elucidate the role of oncogenes in
metastatic disease it will be necessary to employ autopsy
material.
The EGF-receptor and neu proteins are good candidates
for studying multiple metastases since they are stable for up
to 24 h post-mortem. The c-myc protein has a very short
biological life and could not be examined in such studies.
The very limited stability of the c-myc protein also suggests
that care should be taken in interpreting results from archival
material whose provenance is not known.
We are grateful to Lynette Williams for preparing the manuscript.
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